-- 火曜午後、消費関連株は下落し、ステート・ストリート・コンシューマー・ステープルズ・セレクト・セクターSPDR ETF(XLP)は0.3%、ステート・ストリート・コンシューマー・ディスクレショナリー・セレクト・セクターSPDR ETF(XLY)は0.2%それぞれ下落した。 セクター別ニュースでは、レッドブック社の米国既存店売上高は、4月18日までの週で前年同期比6.7%増となり、前週の7%増に続く伸びとなった。「一部の小売業者は、イースター商戦の売上が前年同期比で低迷したと報告しており、昨年の4月のイースター商戦との比較が厳しい状況にある」とレッドブック社は指摘している。春の到来とともに住宅改修用品やアウトドア用品の売上は伸びた一方、生活必需品、食料品、消耗品は横ばいだった。 企業ニュースでは、トラクター・サプライ(TSCO)が発表した第1四半期決算は、ペット用品事業の業績不振により、ウォール街の予想を下回った。同社の株価は10%以上下落した。 D.R.住宅建設大手ホートンズ(DHI)の第2四半期決算は予想を上回ったものの、通期売上高見通しは下方修正した。株価は7%以上上昇した。 スペインの経済紙エクスパンションは火曜日、エスティローダー(EL)がプイグ買収資金として約50億ユーロ(58億8000万ドル)規模の資金調達パッケージを策定するため、JPモルガン(JPM)を起用したと報じた。エスティローダーの株価は1.4%下落した。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.